BACKGROUND: With widespread resistance to antimonials in Visceral Leishmaniasis (VL) in the Indian subcontinent, Miltefosine (MIL) has been introduced as the first line therapy. Surveillance of MIL susceptibility in natural populations of Leishmania donovani is vital to preserve it and support the VL elimination program. METHODOLOGY AND PRINCIPAL FINDINGS: We measured in vitro susceptibility towards MIL and paromomycin (PMM) in L. donovani isolated from VL and PKDL, pre- and post-treatment cases, using an amastigote-macrophage model. MIL susceptibility of post-treatment isolates from cured VL cases (nâ=â13, mean IC(50)±SDâ=â2.43±1.44 µM), was comparable (p>0.05) whereas that from relapses (nâ=â3, mean IC(50)â=â4.72±1.99 µM) was significantly higher (pâ=â0.04) to that of the pre-treatment group (nâ=â6, mean IC(50)â=â1.86±0.75 µM). In PKDL, post-treatment isolates (nâ=â3, mean IC(50)â=â16.13±2.64 µM) exhibited significantly lower susceptibility (pâ=â0.03) than pre-treatment isolates (nâ=â5, mean IC(50)â=â8.63±0.94 µM). Overall, PKDL isolates (nâ=â8, mean IC(50)â=â11.45±4.19 µM) exhibited significantly higher tolerance (p<0.0001) to MIL than VL isolates (nâ=â22, mean IC(50)â=â2.58±1.58 µM). Point mutations in the miltefosine transporter (LdMT) and its beta subunit (LdRos3) genes previously reported in parasites with experimentally induced MIL resistance were not present in the clinical isolates. Further, the mRNA expression profile of these genes was comparable in the pre- and post-treatment isolates. Parasite isolates from VL and PKDL cases were uniformly susceptible to PMM with respective mean IC(50)â=â7.05±2.24 µM and 6.18±1.51 µM. CONCLUSION: The in vitro susceptibility of VL isolates remained unchanged at the end of MIL treatment; however, isolates from relapsed VL and PKDL cases had lower susceptibility than the pre-treatment isolates. PKDL isolates were more tolerant towards MIL in comparison with VL isolates. All parasite isolates were uniformly susceptible to PMM. Mutations in the LdMT and LdRos3 genes as well as changes in the expression of these genes previously correlated with experimental resistance to MIL could not be verified for the field isolates.
Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
米替福新治疗内脏利什曼病和黑热病后皮肤利什曼病后利什曼原虫分离株的药物敏感性
阅读:4
作者:Bhandari Vasundhra, Kulshrestha Arpita, Deep Deepak Kumar, Stark Olivia, Prajapati Vijay Kumar, Ramesh V, Sundar Shyam, Schonian Gabriele, Dujardin Jean Claude, Salotra Poonam
| 期刊: | PLoS Neglected Tropical Diseases | 影响因子: | 3.400 |
| 时间: | 2012 | 起止号: | 2012;6(5):e1657 |
| doi: | 10.1371/journal.pntd.0001657 | ||
特别声明
1、本文转载旨在传播信息,不代表本网站观点,亦不对其内容的真实性承担责任。
2、其他媒体、网站或个人若从本网站转载使用,必须保留本网站注明的“来源”,并自行承担包括版权在内的相关法律责任。
3、如作者不希望本文被转载,或需洽谈转载稿费等事宜,请及时与本网站联系。
4、此外,如需投稿,也可通过邮箱info@biocloudy.com与我们取得联系。
